Astellas Pharma Inc 2014 AR2
The report outlines Astellas Pharma Inc.'s business performance and corporate social responsibility initiatives for fiscal 2013. Key highlights include the global expansion of its overactive bladder franchise with Vesicare and mirabegron, and the rapid growth of its oncology franchise driven by XTANDI. Astellas reshaped its R&D framework to enhance innovation and established Astellas Innovation Management to capture external opportunities. In sustainability, the company advanced its CSR procurement practices, reduced global water withdrawal by 35.3% compared to the fiscal 2005 base year, and achieved its fiscal 2020 biodiversity index target ahead of schedule.
Company: Astellas Pharma Inc
Sector: Manufacturing
Country: Japan
Year: 2014
Type: AR2
Pages: 172
Back to company
Astellas Pharma Inc
Annual Report
The report outlines Astellas Pharma Inc.'s business performance and corporate social responsibility initiatives for fiscal 2013. Key highlights include the global expansion of its overactive bladder franchise with Vesicare and mirabegron, and the rapid growth of its oncology franchise driven by XTANDI. Astellas reshaped its R&D framework to enhance innovation and established Astellas Innovation Management to capture external opportunities. In sustainability, the company advanced its CSR procurement practices, reduced global water withdrawal by 35.3% compared to the fiscal 2005 base year, and achieved its fiscal 2020 biodiversity index target ahead of schedule.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2014
Reporting Period
Apr 1, 2013 - Mar 31, 2014
Fiscal Year
2013
Published
Sep 1, 2014
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Women in Management
Employees